1. At a Glance – Blink and You’ll Miss the Profits
Chemfab Alkalis Ltd is currently valued at ₹584 crore, trades around ₹406, and is behaving like a classic mid-cap chemical stock that forgot its own glory days. Once upon a time, this company flexed 30%+ operating margins, printed cash from caustic soda, and enjoyed a neat negative working capital cycle. Fast-forward to Q3 FY26 and we have sales down 18.5% YoY, PAT at –₹4.45 crore, OPM collapsed to 2.83%, and interest coverage gasping at 1.16x.
ROCE is chilling at 3.32%, ROE at 2.33%, and the stock is down ~60% YoY, which tells you the market has already delivered its judgement — without mercy, without anesthesia.
And yet… promoters still own 72.1%, debt is not nuclear (D/E 0.29), a new electrolyser is live, PVC-O pipes capacity is expanding, and a ₹563 crore greenfield subsidiary project is quietly loading future leverage like a slow-burn thriller.
So the real question:
Is Chemfab Alkalis temporarily sick… or structurally broken?
Let’s dissect this molecule by molecule.
2. Introduction – When Caustic Soda Turns Caustic to Shareholders
Chemfab Alkalis is not a newbie chemical play. Incorporated in 2009, it operates in one of the most boring, cyclical, brutally competitive chemical segments in India — chlor-alkali. This is a business where:
- Power cost decides margins
- Caustic soda prices decide mood
- Chlorine disposal decides survival
In FY23, Chemfab looked smart. Margins were high, capacity utilisation decent, and PVC-O pipes gave a “sunshine infra story” angle. But FY25 and FY26 decided to humble the management.
By Q3 FY26:
- Revenues slid to ₹68.1 crore
- EBITDA shrank to ₹1.93 crore
- Depreciation and interest said “hello darkness my old friend”
- PAT turned negative again
The stock P/E is blank because EPS is –₹9.12. You can’t divide by sadness.
But before we call this a fallen angel or a value trap, we need to understand what Chemfab actually does, where it makes money, and where it bleeds chlorine-scented cash.
3. Business Model – WTF
